BridgeBio Pharma Accounts Payable

BridgeBio Pharma (BBIO) currently reports a accounts payable of $27M as of June 2026. That compares with $26M in the prior-year period — up 4.1% year over year. Use the charts on this page to explore BridgeBio Pharma's accounts payable history and peer comparisons.

BridgeBio Pharma's accounts payable increased from $26M to $27M — a 4.1% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

BridgeBio Pharma reported $27M in accounts payable as of June 2026. That compares with $26M in the prior-year period — up 4.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $27M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for BridgeBio Pharma, and consider following BBIO for alerts when major investors trade the stock.

BridgeBio Pharma is classified in the Healthcare sector. On accounts payable, it currently shows $27M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BBIO with unrelated industries.